FIBRIANT | THE FIBRINOGEN COMPANY
­

Fibriant expands license adding recombinant human (pro)thrombin to existing recombinant fibrinogen capability – Company on track for clinical studies with RecoSeelTM in mild-to-moderate bleeding in 2021

Leiden, The Netherlands, December 5, 2019 – Fibriant B.V., a developer of innovative recombinant fibrin(ogen) technology and products, today announced […]

By |December 5th, 2019|Geen categorie|0 Comments
Load More Posts